Could two old drugs boost chemo for pancreatic cancer?
NCT ID NCT05821556
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding valproic acid and simvastatin to standard chemotherapy can help people with untreated metastatic pancreatic cancer live longer without their disease getting worse. About 240 participants will be randomly assigned to receive either the standard chemo alone or the standard chemo plus the two extra drugs. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
valproic acid and simvastatin combined with gemcitabine/nab-paclitaxel chemotherapy
What this could lead to
If it works, this could point toward a more effective first-line treatment for metastatic pancreatic cancer, potentially slowing disease progression.
What could go wrong
This is an early phase 2 trial with a small sample size. The added drugs may not improve outcomes and could increase side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale
RECRUITINGNaples, Italy, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ramon y Cajal Hospital and Health Research Institute (IRYCIS)
RECRUITINGMadrid, Madrid, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Verona Hospital Trust
RECRUITINGVerona, Verona, 37122, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Università Cattolica Del Sacro Cuore, IRCCS Fondazione Policlinico Universitario Gemelli - Medical Oncology, Roma, Italia
RECRUITINGRoma, Roma, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Università vita e Salute, IRCCS San Raffaele
RECRUITINGMilan, Milano, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••